Navigation Links
Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
Date:3/12/2009

AURORA, Ontario, March 12 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") announced that its registration statement on Form 20-F has been declared effective by the U.S. Securities and Exchange Commission ("SEC").

Accordingly, Helix's common shares are now registered with the SEC pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended. Registration of Helix's shares in the United States allows its shares to be solicited and traded by licensed brokers in the United States in compliance with SEC regulations and blue sky requirements in various states in the United States.

"We are excited for this registration which we believe provides us with a necessary foundation as we plan to move toward larger capital markets," said John Docherty, president of Helix BioPharma. "We are continuing to evaluate our options for our next step as we look to broaden our U.S. investor base and trading liquidity."

The Company's registration statement on Form 20-F is a full registration of the Company's common shares with the SEC as a foreign private issuer similar to a Form 10 filing for a domestic issuer in the United States. Helix's registration statement, as amended, has been filed with the SEC and Canadian Securities Administrators and is available online at www.sec.gov/edgar.shtml and www.sedar.com, respectively.

As a result of the registration statement being declared effective, Helix will be obligated to file continuous disclosure documentation applicable to foreign private issuers with the SEC and will be obligated to prepare a reconciliation of its annual financial statements to generally accepted accounting principles in the United States.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP".

For further information contact:

    Investor & Media Relations
    Ian Stone                         Robert Flamm, Ph.D.
    Russo Partners LLC                Russo Partners LLC
    Tel:  (619) 528-2220              Tel: (212) 845-4226
    Fax:  (619) 528-2297              Email: robert.flamm@russopartnersllc.com
    Email: ian.stone@russopartnersllc.com    www.russopartnersllc.com

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains certain forward-looking statements and information regarding the registration of Helix's common shares with the U.S. Securities & Exchange Commission and Helix's business, which statements and information can be identified by the use of forward-looking terminology such as "believe," "look," "next", "will," "future", "anticipation", "plan", "developing", or variations thereon, or comparable terminology referring to future events or results. Forward looking statements and information are statements and information about the future and are inherently uncertain. Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks and uncertainties including without limitation: uncertainty whether Helix's shares will be actively solicited and traded by licensed brokers in the U.S. or that Helix's liquidity and U.S. investor base will be expanded, which may not occur due to a number of factors including potential lack of demand for Helix's shares, the fact that Helix's shares will be "penny stock" and subject to certain restrictions, and the state of the financial and stock markets generally; uncertainty whether the Company's products under development, including Topical Interferon Alpha-2b and L-DOS47 will be successfully developed and commercialized as a drug or at all; the need for additional clinical trials, the occurrence and success of which cannot be assured; product liability and insurance risks; research and development risks; the risk of technical obsolescence; the need for further regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix's products; as well as a description of other risks and uncertainties affecting Helix and its business, as contained in news releases and filings with the securities regulatory authorities, including its latest Annual Information Form, at www.sedar.com and Form 20-F at www.sec.gov/edgar.shtml, any of which could cause actual results to vary materially from current results or Helix's anticipated future results. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
2. Helix BioPharma Announces Q1 2009 Financial Results
3. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
4. Helix BioPharma Corp. Announces Fiscal 2008 Results
5. Helix Biopharma Closes $11.4 Million Private Placement
6. Helix BioPharma Announces $11.4 Million Private Placement
7. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
8. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
9. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
10. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
11. Helix BioPharma reports Q2 2008 highlights, financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  PTC Therapeutics, Inc. ... annual STRIVE (Strategies to Realize Innovation, Vision and ... (DMD). STRIVE provides funds to patient advocacy organizations ... make meaningful contributions to the rare disease community ... of future patient advocates. Mary ...
(Date:2/11/2016)... , Feb. 11, 2016  Vermillion, Inc. (NASDAQ: ... gynecologic disease, today announced the formation of the Steering ... --> --> Pelvic masses can ... diagnosis and management. Once pregnancy is ruled out, pelvic ... and ovaries, advanced endometriosis, benign ovarian tumors and gastrointestinal ...
(Date:2/11/2016)... , Feb. 11, 2016  Wellcentive today announced ... Portland, Oregon -based community care organization ... population health analytics, quality reporting and care management ... strengthen its team of quality managers, analysts and ... the provider groups serving FamilyCare members. ...
(Date:2/11/2016)... 2016   BioInformant announces the February 2016 ... Products, Opportunities, Tools, and Technologies – Market Size, Segments, ... The first and only ... industry, BioInformant has more than a decade of historical ... by stem cell type. This powerful 175 page global ...
Breaking Biology Technology:
(Date:2/9/2016)... Feb. 9, 2016 Vigilant Solutions announces today that ... (LPR) to develop a lead in a difficult homicide case. ... data to locate the suspect vehicle. Due to the ongoing ... have been omitted at the agency,s request. ... explains, "Our victim was found deceased at an intersection here ...
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... compared with fourth quarter of 2014. Gross margin was 46% ... Earnings per share increased to SEK 6.39 (loss: 0.49). ... , --> --> January ... (233.6), up 1,142% compared with 2014. Gross margin was 43% ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 ... healthcare facilities are primarily focused on medical ... that measure point-of-care parameters. Wearable devices that ... a user,s freedom of movement are being ... sensors for human biomedical signal acquisition coupled ...
Breaking Biology News(10 mins):